On November 4, Bayer China announced that the State Drug Administration has approved Hercinol® monotherapy, a novel targeted treatment for lung cancer, to treat adult patients with unresectable locally advanced or metastatic non-small cell lung cancer with HER2 activating mutations.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.